[6-chloro-4-(7-chloro-imidazo[1,2-a]pyridin-3-yl)-pyridin-2-yl]-methyl-amine | 1146615-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: [6-chloro-4-(7-chloro-imidazo[1,2-a]pyridin-3-yl)-pyridin-2-yl]-methyl-amine
• 英文别名: [6-Chloro-4-(7-chloro-imidazo[1,2-a]pyridin-3-yl)-pyridin-2-yl]-methyl-amine；6-chloro-4-(7-chloroimidazo[1,2-a]pyridin-3-yl)-N-methylpyridin-2-amine
• CAS: 1146615-99-7
• 化学式: C₁₃H₁₀Cl₂N₄
• 分子量: 293.155
• InChiKey: REYUNQXPGLPNQI-UHFFFAOYSA-N

物化性质

• 密度：
  1.47±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [6-chloro-4-(7-chloro-imidazo[1,2-a]pyridin-3-yl)-pyridin-2-yl]-methyl-amine 、 苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 0.17h， 生成 [4-(7-chloro-imidazo[1,2-a]pyridin-3-yl)-6-phenyl-pyridin-2-yl]-methyl-amine
  参考文献：
  名称：

  [EN] IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  公开号：

  WO2009050183A3
• 作为产物：
  描述：

  7-chloro-3-(2,6-dichloro-pyridin-4-yl)-imidazo[1,2-a]pyridine 、 甲胺 在 caesium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 [6-chloro-4-(7-chloro-imidazo[1,2-a]pyridin-3-yl)-pyridin-2-yl]-methyl-amine
  参考文献：
  名称：

  [EN] IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  公开号：

  WO2009050183A3

文献信息

• Organic Compounds
  申请人：Shaw Duncan

  公开号：US20100210641A1

  公开（公告）日：2010-08-19

  Compounds of formula I: in free or salt or solvate form, where R 1 , R 2 , R 3 and R 20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.

  式I的化合物：以自由或盐或溶剂形式存在，其中R1，R2，R3和R20具有规范中指定的含义，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的方法。这些化合物对于治疗炎症或阻塞性呼吸道疾病，如肺动脉高压，肺纤维化，肝纤维化，癌症，肌肉疾病，如肌肉萎缩和肌肉营养不良，以及全身性骨骼疾病，如骨质疏松症非常有用。
• Organic compounds
  申请人：Shaw Duncan

  公开号：US08367662B2

  公开（公告）日：2013-02-05

  Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.

  公式I的化合物：以自由形式、盐形式或溶剂合形式存在，其中R1、R2、R3和R20的含义如规范所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了包含这些化合物的药物组合物和制备这些化合物的过程。这些化合物可用于治疗炎性或阻塞性呼吸道疾病，如肺动脉高压、肺纤维化、肝纤维化、癌症、肌肉疾病，如肌肉萎缩和肌肉萎缩症，以及全身骨骼疾病，如骨质疏松症。
• IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS
  申请人：Novartis AG

  公开号：EP2212323B1

  公开（公告）日：2012-08-15
• US8367662B2
  申请人：——

  公开号：US8367662B2

  公开（公告）日：2013-02-05
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2009050183A2

  公开（公告）日：2009-04-23

  Compounds of formula I: in free or salt or solvate form, where R1, R2, R3 and R20 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.